Abstract
Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Current HIV Research
Title: Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples
Volume: 6 Issue: 2
Author(s): Paolo Fabris, Maria R. Biasin, Maria T. Giordani, Laura Berardo, Vania Menini, Antonio Carlotto, Maria G. Miotti, Vinicio Manfrin, Vincenzo Baldo, Gaia Nebbia and Domenico Infantolino
Affiliation:
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Abstract: Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Export Options
About this article
Cite this article as:
Fabris Paolo, Biasin R. Maria, Giordani T. Maria, Berardo Laura, Menini Vania, Carlotto Antonio, Miotti G. Maria, Manfrin Vinicio, Baldo Vincenzo, Nebbia Gaia and Infantolino Domenico, Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples, Current HIV Research 2008; 6 (2) . https://dx.doi.org/10.2174/157016208783885029
DOI https://dx.doi.org/10.2174/157016208783885029 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Designing Peptidomimetics
Current Topics in Medicinal Chemistry MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells
Current Topics in Medicinal Chemistry Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Cytotoxicity and Cell Death Mechanisms Induced by a Novel Bisnaphthalimidopropyl Derivative against the NCI-H460 non-small Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Pharmaceutical Design A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine
Current Topics in Medicinal Chemistry Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety Synthesis, Characterization, Quantum-Chemical Calculations and Cytotoxic Activity of 1,8-Naphthalimide Derivatives with Non-Protein Amino Acids
Anti-Cancer Agents in Medicinal Chemistry Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Production of High-purity Radium-223 from Legacy Actinium-Beryllium Neutron Sources
Current Radiopharmaceuticals